文献速递瓣膜外科

英国心脏瓣膜术后抗血栓治疗现状调查

Antithrombotic therapy after heart valve surgery: contemporary practice in the UK.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2024-01-01

该研究通过电子邮件问卷调查英国所有顾问心脏外科医生,评估生物瓣主动脉瓣置换、生物瓣二尖瓣置换或二尖瓣修复术后窦性心律且无其他抗血栓指征患者的抗血栓处方模式。共260名来自36个中心的顾问医生中103人(40%)回复,33个中心(92%)至少1人回复。结果显示各术式抗血栓策略差异显著,缺乏高质量证据指导实践,作者强调需要随机研究。

要点

  • 生物瓣主动脉瓣置换后76%医生首选抗血小板,53%处方终身治疗,仅8%推荐初始口服抗凝。
  • 生物瓣二尖瓣置换后48%医生初始口服抗凝(vs 42%抗血小板),66%后续处方终身抗血小板。
  • 二尖瓣修复后推荐终身单用抗血小板34%、3个月口服抗凝后20%、无抗血栓药20%、3个月口服抗凝16%。

核心结论

  • 英国心脏瓣膜术后抗血栓药物使用存在显著差异,缺乏高质量证据指导实践,作者强调需要随机研究。

研究设计与样本

  • 研究设计为电子邮件问卷调查,对象为英国所有顾问心脏外科医生,共识别来自36个中心的260名顾问医生。

主要发现

  • 共103名(40%)顾问医生回复,33个中心(92%)至少有1名回复者。
  • 生物瓣主动脉瓣置换后,76%医生首选初始抗血小板治疗,53%处方终身治疗,仅8%推荐初始口服抗凝。
  • 生物瓣二尖瓣置换后,48%医生采用初始口服抗凝策略(vs 42%抗血小板),66%后续处方终身抗血小板治疗。
  • 二尖瓣修复后,推荐终身单用抗血小板药物34%、3个月口服抗凝后20%、无抗血栓药物20%、3个月口服抗凝16%。
  • 二尖瓣修复合并房颤患者,医生推荐华法林38%、直接口服抗凝药37%、两者无偏好25%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There is a lack of high-quality data informing the optimal antithrombotic drug strategy following bioprosthetic heart valve replacement or valve repair. Disparity in recommendations from international guidelines reflects this. This study aimed to document current patterns of antithrombotic prescribing after heart valve surgery in the UK. METHODS: All UK consultant cardiac surgeons were e-mailed a custom-designed survey. The use of oral anticoagulant (OAC) and/or antiplatelet drugs following bioprosthetic aortic valve replacement or mitral valve replacement, or mitral valve repair (MVrep), for patients in sinus rhythm, without additional indications for antithrombotic medication, was assessed. Additionally, we evaluated anticoagulant choice following MVrep in patients with atrial fibrillation. RESULTS: We identified 260 UK consultant cardiac surgeons from 36 units, of whom 103 (40%) responded, with 33 units (92%) having at least 1 respondent. The greatest consensus was for patients undergoing bioprosthetic aortic valve replacement, in which 76% of surgeons favour initial antiplatelet therapy and 53% prescribe lifelong treatment. Only 8% recommend initial OAC. After bioprosthetic mitral valve replacement, 48% of surgeons use an initial OAC strategy (versus 42% antiplatelet), with 66% subsequently prescribing lifelong antiplatelet therapy. After MVrep, recommendations were lifelong antiplatelet agent alone (34%) or following 3 months OAC (20%), no antithrombotic agent (20%), or 3 months OAC (16%). After MVrep for patients with established atrial fibrillation, surgeons recommend warfarin (38%), a direct oral anticoagulant (37%) or have no preference between the 2 (25%). CONCLUSIONS: There is considerable variation in the use of antithrombotic drugs after heart valve surgery in the UK and a lack of high-quality evidence to guide practice, underscoring the need for randomized studies.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Laskar N, Bayliss CD, Kirmani BH, et al. Antithrombotic therapy after heart valve surgery: contemporary practice in the UK. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 38704867. doi:10.1093/icvts/ivae089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。